Eton Pharmaceuticals’ (ETON) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock, up from their prior price objective of $11.00. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.17) EPS, Q1 2025 earnings at $0.05 EPS, Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.37 EPS, FY2026 earnings at $0.81 EPS, FY2027 earnings at $1.25 EPS and FY2028 earnings at $1.58 EPS.

Separately, Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $12.74 on Tuesday. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $12.77. The business has a fifty day moving average of $8.37 and a two-hundred day moving average of $5.42. The company has a market cap of $329.15 million, a P/E ratio of -57.91 and a beta of 1.25.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 11,248 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was acquired at an average cost of $7.22 per share, with a total value of $81,210.56. Following the purchase, the insider now directly owns 2,730,000 shares in the company, valued at approximately $19,710,600. This trade represents a 0.41 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders have bought 85,600 shares of company stock valued at $462,674. Insiders own 14.89% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals during the third quarter worth $54,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals during the third quarter valued at $90,000. Renaissance Technologies LLC increased its position in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at about $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.